<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573935</url>
  </required_header>
  <id_info>
    <org_study_id>DMSG 03/14</org_study_id>
    <secondary_id>2014-002187-32</secondary_id>
    <nct_id>NCT02573935</nct_id>
  </id_info>
  <brief_title>Clarithromycin in Multiple Myeloma Induction Therapy</brief_title>
  <acronym>CLAIM</acronym>
  <official_title>A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Gregersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the potential synergic anti-myeloma activity of clarithromycin when&#xD;
      combined with VCD induction therapy in patients with newly diagnosed multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The survival in younger myeloma patients improved in the nineties with the introduction of&#xD;
      high-dose melphalan with autologous stem cell support (HDT). However, all patients will&#xD;
      eventually experience relapse after HDT and there is a need for improvement of the response&#xD;
      after HDT. The choice of induction treatment before HDT affects the outcome after induction&#xD;
      therapy as well as the outcome after HDT.&#xD;
&#xD;
      Clarithromycin is a macrolide antibiotic frequently utilized in the treatment of respiratory&#xD;
      tract infections and is often used in patients with known hypersensitivity to beta-lactam&#xD;
      antibiotic. Besides antibiotic activity, clarithromycin may exert immunomodulatory and&#xD;
      anti-inflammatory effects. The toxicity profile of clarithromycin is favourable and the cost&#xD;
      is very low.&#xD;
&#xD;
      Studies on cell lines have shown that clarithromycin attenuates autophagy in myeloma cells&#xD;
      and a recent study has demonstrated that treatment with clarithromycin enhanced&#xD;
      bortezomib-induced cytotoxicity in myeloma cells. Phase II studies without control groups&#xD;
      have indicated that clarithromycin might enhance the effect of the thalidomide and&#xD;
      lenalidomide. A case-matched analysis compared patients at one centre receiving&#xD;
      clarithromycin, lenalidomide and dexamethasone with an equal number of patients at another&#xD;
      centre receiving lenalidomide and dexamethasone. This study indicated a favourable effect of&#xD;
      clarithromycin with a higher frequency of complete response, very-good-partial-response or&#xD;
      better response and progression-free survival. However, there is a need for controlled&#xD;
      studies to determine whether clarithromycin might enhance the effect of other myeloma agents.&#xD;
&#xD;
      This randomized placebo-controlled study will include 160 patients with newly diagnosed&#xD;
      multiple myeloma eligible for HDT. The study evaluates the potential synergic anti-myeloma&#xD;
      activity of clarithromycin when combined with VCD induction therapy in patients with newly&#xD;
      diagnosed multiple myeloma, and is conducted by the Danish Myeloma Study Group (DMSG) at&#xD;
      seven clinics in Denmark. The first patient was included in May 2015 and enrolment is&#xD;
      expected to continue until October 2016. The study ends when the last included patient has&#xD;
      been followed for two months after HDT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Suspected side effects to the combination of clarithromycin and VCD (bortezomib,&#xD;
    cyclophosphamide and dexamethasone)&#xD;
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of number of participants with very good partial response or better response after HDT in patients treated with three courses of VCD combined with clarithromycin or placebo</measure>
    <time_frame>Five months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of number of participants with sCR, CR, PR, PD or SD in the treatment groups after induction therapy and HDT, respectively</measure>
    <time_frame>Five months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of frequency of infections in patients treated VCD combined with clarithromycin or placebo</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of number of stem cells harvested in patients treated with clarithromycin and placebo in combination with VCD</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotoxicity assessed by FACT/GOG-Ntx, Version 4.0</measure>
    <time_frame>Five months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORTC QLQ-MY20</measure>
    <time_frame>Five months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORTC QLQ-C30</measure>
    <time_frame>Five months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of adverse events in patients treated VCD combined with clarithromycin or placebo assessed by CTCAE v4.0</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clarithromycin combined with VCD induction therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo combined with VCD induction therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>p.o. clarithromycin 500 mg twice daily for 63 days</description>
    <arm_group_label>Clarithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily for 63 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VCD induction therapy</intervention_name>
    <description>Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)</description>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Myeloma diagnosis according to IMWG criteria&#xD;
&#xD;
          -  Treatment demanding disease&#xD;
&#xD;
          -  High-dose melphalan with stem cell support scheduled as a part of the treatment&#xD;
&#xD;
          -  Signed informed consent given prior to any study related activities&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allogeneic transplantation scheduled as a part of the treatment&#xD;
&#xD;
          -  Myeloma treatment prior to entry in the study, except radiotherapy,&#xD;
             bisphosphonates/denosumab or corticosteroids for symptom control&#xD;
&#xD;
          -  Concurrent disease making clarithromycin treatment unsuitable&#xD;
&#xD;
          -  Positive pregnancy test (only applicable for women with childbearing potential)&#xD;
&#xD;
          -  Known or suspected hypersensitivity or intolerance to clarithromycin&#xD;
&#xD;
          -  Prolonged QT corrected (QTc) interval ( &gt; 500 msec on screening ECG)&#xD;
&#xD;
          -  Concurrent treatment with cabergoline, fluconazole, ketoconazole, pimozide,&#xD;
             quetiapine, sirolimus, verapamil, tacrolimus, ergot alkaloid, simvastatin or other&#xD;
             statins&#xD;
&#xD;
          -  Uncontrolled or severe cardiovascular disease including myocardial infarction within 6&#xD;
             months of enrolment, uncontrolled angina or known cardiac amyloidosis&#xD;
&#xD;
          -  Severe renal dysfunction (estimated creatinine clearance &lt;10 mL/min)&#xD;
&#xD;
          -  Serious medical or psychiatric illness which, in the judgment of the investigator,&#xD;
             would make the patient inappropriate for entry into the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Gregersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Roskilde Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol. 2010 Sep;85(9):664-9. doi: 10.1002/ajh.21777.</citation>
    <PMID>20645430</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 8, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Gregersen</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Induction Chemotherapy</keyword>
  <keyword>Transplantation, Autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 16, 2018</submitted>
    <returned>January 29, 2019</returned>
    <submitted>July 5, 2019</submitted>
    <returned>August 15, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

